News

Does the 23andMe Acquisition Make Regeneron a Buy Now?
Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...
Pharmabiz1h
Predictive Oncology breakthrough coincides with Regeneron Pharma’s acquisition of 23andMe for $256 million: Artificial intelligence meets genomics
Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...
Regeneron to buy 23andMe out of bankruptcy for $256 million
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...
Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
The Hudson Independent1d
Regeneron Enters into Agreement to Acquire Consumer Genetics Business
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...